Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Vantas | Histrelin acetate | Cancer, prostate | Do not list | Complete | ||
Sutent | Sunitinib malate | Cancer, Metastatic renal cell carcinoma | Do not list | Complete | ||
Iressa | Gefitinib | Cancer, Lung , non-small cell | Do not list | Complete | ||
Tarceva | Erlotinib | Cancer, Lung , non-small cell | List with clinical criteria and/or conditions | Complete | ||
Talzenna | talazoparib | Breast cancer | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Darzalex | Daratumumab | BMP for Multiple Myeloma (newly diagnosed) | Reimburse with clinical criteria and/or conditions | Complete | ||
Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Blepharospasm | List in a similar manner | Complete | ||
Hemlibra | emicizumab | Bleeding prevention, hemophilia A | Reimburse with clinical criteria and/or conditions | Complete | ||
Enablex | Darifenacin hydrobromide | Bladder, overactive | List with clinical criteria and/or conditions | Complete | ||
Vesicare | Solifenacin succinate | Bladder, overactive | List with clinical criteria and/or conditions | Complete |